Sara Patel

Ms. Patel’s experience includes advising:

Strategic Intellectual Property Transactions

• Pharmaceutical Investment Company (Lifera), a biopharmaceutical company wholly owned by the Public Investment Fund (PIF) of Saudi Arabia on a strategic collaboration and JV with Centogene, a German life sciences company focused on data-driven answers in rare and neurodegenerative diseases, to provide AI driven diagnostics expertise and the establishment of advanced laboratory and bioinformatics infrastructure in KSA 
• CollPlant Biotechnologies, a regenerative medicine company, in a worldwide exclusive development and commercialization agreement for dermal and soft tissue filler products with Allergan Aesthetics, an AbbVie company
• A leading US medical devices company on a strategic IP license agreement for the development and commercialization of its medical technology platform
• GSK on variety of matters including supply arrangements
• A world-leading GCC hospital in relation to agreements for the global supply of medicinal product and medical devices
• A UK-based DNA/RNA sequencing company on a variety of intellectual property and complex commercial agreements*
• A KSA based pharmaceutical company in relation to its strategic license and distribution agreements*

Joint Ventures and M&A

• atai Life Sciences in a strategic investment in Beckley Psytech to accelerate the clinical development of short-duration psychedelics, on intellectual property and commercial matters 
• A leading investor in a series C financing round for a digital health company that develops and provides AI driven non-invasive medical diagnostics solutions to support healthcare provider diagnosis, pharmaceutical development, patient monitoring, and treatment decision-making
• Norgine, a Netherlands-based specialty pharmaceutical company on regulatory matters in its US$2 billion sale to Goldman Sachs
• A multinational world-leading pharmaceutical company on intellectual property, commercial and regulatory matters in its US$1.5 billion acquisition of a UK biotech company
• Astorg on its binding agreement to acquire CordenPharma, a leading pharmaceutical contract development and manufacturing organization, from ICIG, a privately owned industrial group
• Silver Lake Partners on its €3.5 billion investment in IVC Evidensia, a leading European veterinary care provider
• Novo Holdings on leading a Series D funding round for Quanta Dialysis Technologies, a medical technology leader delivering on its vision for more flexible and accessible dialysis care and acquisition of BBI Group, a leading supplier of products and services to the global diagnostics and life sciences industries
• Nordic Capital in its US$846 million acquisition of Advanz Pharma, a UK-based specialty pharmaceutical company
• A global medical device company on its joint venture with a world-leading multinational company for the manufacture and distribution of spectacle lenses
• Owens & Minor, Inc. a global healthcare solutions company on the sale of its European logistics business, Movianto, to EHDH Holding Group*
• CBPE Capital on its acquisition of Simbec-Orion, an international CRO*
• A leading Middle Eastern pharmaceutical company on its JV with an Indian generics company*

Regulatory

• Various pharmaceutical and medical technology companies regarding pharmacovigilance, clinical trials and other study agreements
• A global social media platform in connection with its medical device product launch in the UAE
• A leading Germany-based medical device company in connection with the supply and distribution of medical devices in the UAE
• Various global pharmaceutical clients in relation to their regulatory compliance programs and interactions with HCPs*
• Amplifon SpA in connection with its medical device product launch in the UK and EU* 
• A UK headquartered pharmaceutical company in relation to product launch and the supply of medicinal product to the UAE, Kuwait, and Qatar*

*Matter handled prior to joining Latham